|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
During crisis, patients presented with less acute coronary syndrome (ACS - 45.5% vs. 39.9%, p < 0.001).
|
29601956 |
2020 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Information on the relationship between circulating cholesteryl ester transfer protein (CETP) levels and coronary heart disease (CHD) incidence (and also, therefore, acute coronary syndrome [ACS]) is conflicting.
|
31504738 |
2020 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe the incidence, timing, and characteristics of stent thrombosis and its consequences in patients with atrial fibrillation (AF) in the AUGUSTUS trial<sup>1</sup> who received a coronary stent during their qualifying admission (acute coronary syndrome [ACS] or elective percutaneous coronary intervention [PCI]) and the randomized treatment effects of low-dose aspirin (compared with placebo) and apixaban (compared with vitamin K antagonist [VKA]) on the risk of stent thrombosis.
|
31707833 |
2020 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Multivariable analysis identified diabetes (BRI of patients with diabetes vs. patients without diabetes: 0.34 ± 0.13 vs. 0.58 ± 0.22; p = .002) and presence of Peri-strut low intensity areas (PSLIA, BRI of 10 patients with PSLIA vs. 26 patients without PSLIA: 0.44 ± 0.21 vs. 0.61 ± 18; p = .027) as independent predictors for a prolonged BRS resorption, whereas the resorption rate in ACS patients (STEMI, NSTEMI, and unstable angina; n = 13) was significantly higher as compared to patients without ACS (0.62 ± 0.17 vs. 0.43 ± 0.24; p = .012).
|
30945432 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
No interaction was observed according to patients' risk profile or the rate of diabetes and ACS.
|
31730255 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
40 ACS patients with prior history of CHD and diabetes while the onset time of diabetes preceded that of CHD by more than 2 years were enrolled as the DACS group(diabetic ACS group).
|
30670045 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Diabetes is not associated with increased rates of free flap failure: Analysis of outcomes in 6030 patients from the ACS-NSQIP database.
|
29719063 |
2019 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
This study aimed to examine the impact of diabetes on postoperative outcomes following surgical management of pressure ulcers using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database.
|
30663823 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the MAIN-COMPARE study including 2,240 patients with LMCA disease treated with PCI (n = 1102) or CABG (n = 1138), we examined interaction between acuity of clinical presentation (acute coronary syndromes [ACS] or non-ACS) and revascularization strategy on 10-year outcomes.
|
31655415 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prospective cohort study of 75 stable patients with CAD and 3 differing clinical profiles (stable angina [SA]; remote myocardial infarction [MI]; repetitive acute coronary syndrome [ACS]) and 25 controls without angiographic CAD, each with 15 hs-cTnT measurements over 1 year.
|
31679620 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All patients admitted for acute coronary syndrome at Östersund hospital between 2010-2014 were screened for the randomized controlled NAILED-ACS trial.
|
31427637 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial.
|
31012853 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Methods and Results The TRANSLATE -ACS (Treatment with ADP Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) study included 11 108 MI patients treated with percutaneous coronary intervention and discharged alive on a P2Y<sub>12</sub> inhibitor from 233 US hospitals.
|
31070112 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Methods and Results To understand the cost drivers during hospitalization for acute MI and in the following year, we prospectively studied 11 969 patients with acute MI undergoing percutaneous coronary intervention at 233 US hospitals (2010-2013) from the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) registry.
|
30975005 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among them, 10 628 patients (1.9%), including 6780 (1.2%) with acute coronary syndrome ( ACS ) and 3848 (0.7%) with stable coronary artery disease, were ≥90 years of age.
|
30791799 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Between November 2014 and November 2016, we collected health-related quality of life data among 1261 participants in the ACS QUIK trial (Acute Coronary Syndrome Quality Improvement in Kerala).
|
30755027 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, it is not easy to make a complete changeover to NOACs in real-world clinical practice because NOACs still have challenges in specific patient populations (eg, Asian patients, NVAF patients presenting with acute coronary syndrome [ACS], dialysis patients with NVAF, patients with cancer-associated VTE, etc.).
|
31632045 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analyses were repeated stratified by whether or not the procedure had been performed in the setting of an acute coronary syndrome ( ACS ).
|
30642222 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 1,121,359 cases (103,887 EVT cases for critical limb ischemia [CLI] or intermittent claudication and 1,017,472 PCI cases for acute coronary syndrome [ACS] or stable angina) were analyzed.
|
31730004 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background The prognostic significance of obstructive sleep apnea ( OSA ) in patients with acute coronary syndrome ( ACS ) in the contemporary era is unclear.
|
30636505 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conflicting evidence exists about the impact of marital status on the outcomes of patients with acute coronary syndrome ( ACS ).
|
31266391 |
2019 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dialysis patients had more comorbidities than nondialysis patients and higher rates of complications including in-hospital mortality (3.3% vs. 1.5%, respectively, in the acute coronary syndrome [ACS] cohort, 0.2% vs. 0.1% in the non-ACS cohort) and bleeding complications requiring blood transfusion (1.1% vs. 0.4% in ACS, 0.5% vs. 0.2% in non-ACS).
|
30467967 |
2019 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
There were 20.8% of patients with NSTE-ACS, 93.8% with hypertension, 35.4% with diabetes, 52.1% had previous MI, and 47.9% and 14.6% underwent prior PCI and coronary artery bypass grafting, respectively.The device success rate was 100%.
|
29192951 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Statin use was highest for recent ACS and lowest for DM alone.
|
29499359 |
2018 |
|
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection.
|
29483656 |
2018 |